Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Qingdao Haier Biomedical CoSHSE:688139 +0.52%83 ROC (Joel Greenblatt) % is 25.09% as of Jun. 2026, which is 35% below its 10-year median of 38.64. GuruFocus rates SHSE:688139 with a GF Score™ of 83/100 and a GF Value™ of ¥37.04 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 838 Medical Devices & Instruments companies, Qingdao Haier Biomedical Co ranks better than 72.2% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Qingdao Haier Biomedical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 25.09%.
The historical rank and industry rank for Qingdao Haier Biomedical Co's ROC (Joel Greenblatt) % or its related term are showing as below:
SHSE:688139'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 13.31 Med: 38.64 Max: 236.48
Current: 22.72
During the past 10 years, Qingdao Haier Biomedical Co's highest ROC (Joel Greenblatt) % was 236.48%. The lowest was 13.31%. And the median was 38.64%.
SHSE:688139's ROC (Joel Greenblatt) % is ranked better than 72.2% of 838
companies
in the Medical Devices & Instruments industry
Industry Median: 4.64
vs SHSE:688139: 22.72
Qingdao Haier Biomedical Co (SHSE:688139) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Qingdao Haier Biomedical Co ROC (Joel Greenblatt) % Chart
SHSE:688139 vs ABT, SYK, MDT: ROC (Joel Greenblatt) % Comparison
For the Medical Devices subindustry, Qingdao Haier Biomedical Co's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Qingdao Haier Biomedical Co ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Qingdao Haier Biomedical Co's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Qingdao Haier Biomedical Co's ROC (Joel Greenblatt) % falls into.
Qingdao Haier Biomedical Co ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 25.09% mean?
Qingdao Haier Biomedical Co (SHSE:688139) has a ROC (Joel Greenblatt) % of 25.09% as of Jun. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Qingdao Haier Biomedical Co and its competitors. This is 35% below median its historical median of 38.64. Over the past decade, Qingdao Haier Biomedical Co's ROC (Joel Greenblatt) % has ranged from 13.31 to 236.48. According to the industry distribution chart, Qingdao Haier Biomedical Co ranks #233 out of 838 companies in the Medical Devices & Instruments industry, placing it in the top 27.8%.
Is Qingdao Haier Biomedical Co's ROC (Joel Greenblatt) % too high?
Qingdao Haier Biomedical Co's current ROC (Joel Greenblatt) % of 25.09% is 35% below median its 10-year median of 38.64. Over the past 10 years, this metric has ranged from a low of 13.31 to a high of 236.48. The Medical Devices & Instruments industry median ROC (Joel Greenblatt) % is 4.64. Qingdao Haier Biomedical Co's value of 25.09% is 440.7% above this industry median. Based on the distribution chart, Qingdao Haier Biomedical Co ranks #233 out of 838 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Qingdao Haier Biomedical Co has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Qingdao Haier Biomedical Co's ROC (Joel Greenblatt) % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Qingdao Haier Biomedical Co ranks #233 out of 838 companies for ROC (Joel Greenblatt) %. This puts Qingdao Haier Biomedical Co in the upper half of its industry. The industry median ROC (Joel Greenblatt) % is 4.64. Qingdao Haier Biomedical Co's value of 25.09% is 440.7% above this benchmark. Historically, Qingdao Haier Biomedical Co's own ROC (Joel Greenblatt) % has ranged from 13.31 to 236.48 over the past decade. While the company's 10-year median is 38.64 vs. the industry median of 4.64, Qingdao Haier Biomedical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 4.64, based on 838 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Qingdao Haier Biomedical Co's current ROC (Joel Greenblatt) % of 25.09% is 440.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Qingdao Haier Biomedical Co and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 4.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Qingdao Haier Biomedical Co's current ROC (Joel Greenblatt) % is 25.09%, which is 35% below median its own 10-year median of 38.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qingdao Haier Biomedical Co stock overvalued right now?
Based on GuruFocus' analysis, Qingdao Haier Biomedical Co (SHSE:688139) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥37.04, compared to a current price of ¥30.80 — trading 16.8% below its estimated fair value. The current ROC (Joel Greenblatt) % is 25.09%, which is 35% below median its 10-year median of 38.64 and 440.7% above the Medical Devices & Instruments industry median of 4.64. Qingdao Haier Biomedical Co's overall GF Score™ is 83/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Qingdao Haier Biomedical Co (SHSE:688139), the current ROC (Joel Greenblatt) % is 25.09% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Qingdao Haier Biomedical Co (SHSE:688139) Overvalued in 2026?
Based on GuruFocus' analysis, Qingdao Haier Biomedical Co stock appears to be undervalued.
The current stock price of ¥30.80 is trading 16.8% below its estimated GF Value™ of ¥37.04.
GuruFocus considers Qingdao Haier Biomedical Co to be Modestly Undervalued.
Key valuation signals for SHSE:688139:
ROC (Joel Greenblatt) %: 25.09% (35% below median its 10-year median of 38.64)
GF Value™: ¥37.04 vs. price of ¥30.80 (16.8% below fair value)
Industry Position: 440.7% above the Medical Devices & Instruments median (#233 of 838)
No single metric tells the full story. See the SHSE:688139 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Qingdao Haier Biomedical Co Ltd is engaged in designing, manufacturing, marketing and sales of low temperature storage equipment for biomedical samples. The company provides provides complete storage solutions for biological sample banks, blood safety, vaccine safety, medical supplies and reagent safety.
83GF Score
Get the complete analysis for SHSE:688139
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688139 has been successfully added to your 
